Endocrine therapy alongside CDK4/6 inhibitors

CDK4/6 inhibitors, such as ribociclib, palbociclib and abemaciclib, are tablets that block proteins cancer cells use to divide. When taken together with hormone therapy, they make hormone treatment work considerably better. In metastatic hormone receptor positive, HER2-negative breast cancer, this combination is now a standard first treatment, and it has helped many women control their cancer for longer and live longer. In some higher-risk early breast cancers, a CDK4/6 inhibitor is also added for a set period after surgery.

How the two treatments work together

Hormone therapy cuts off the oestrogen signal that tells the cancer to grow. The CDK4/6 inhibitor blocks the cell's machinery for dividing. Attacking both steps at once makes it harder for the cancer to keep growing or to become resistant.

Which hormone therapy is paired with it

Usually an aromatase inhibitor such as letrozole, or fulvestrant, an injection that breaks down the oestrogen receptor. Premenopausal women also receive ovarian suppression injections so the hormone therapy can work fully.

Who may not be suitable

People with certain heart rhythm problems, significant liver disease, or very low blood counts, and those taking medicines that interact strongly. Your oncologist chooses the drug and plan accordingly.

In metastatic hormone-sensitive breast cancer, adding a CDK4/6 inhibitor to hormone therapy is one of the most important advances of recent years. Many women keep their cancer controlled for a long time on this combination. It does not make metastatic cancer go away for good, and eventually most cancers adapt.

Low white counts are common but usually manageable

The drop in white cells with ribociclib and palbociclib is expected and rarely leads to serious infection. It is managed by pausing or lowering the dose rather than stopping.

Dose reductions are normal

Many women need a lower dose at some point. Studies suggest this does not reduce how well the treatment works.

Cost is a real barrier

These drugs are expensive in India, although prices and support options change over time. Ask early about assistance programmes.

What this page cannot tell you

It cannot tell you which drug suits you or how long it will work. Ask your oncologist about your options.

The combination is taken at home, but it needs careful routines and regular contact with your team, particularly in the first months.

Keep up blood tests

Blood tests are frequent at first, often every two weeks, then monthly. They guide dose changes and keep treatment safe.

Watch for infection

Although serious infections are uncommon, report a fever, chills or feeling very unwell promptly, especially when counts are low.

Check every new medicine

Some antibiotics, antifungals, heart medicines and herbal products interact with CDK4/6 inhibitors. Always ask your team or pharmacist before starting something new, including grapefruit or pomegranate juice with some drugs.

The first few months are when side effects and dose adjustments are most likely, so knowing what to expect helps you settle into treatment.

Frequent early checks

Blood counts are often checked every two weeks for the first couple of cycles, and heart tracings or liver tests are added for some drugs. These visits usually become less frequent once your dose is settled.

Early dose changes

It is common for the dose to be paused for a week or lowered after the first cycles, usually because of low white counts or loose motions. This is a routine part of finding the right dose, not a sign of failure.

Finding a routine

Taking the tablets at the same time each day, with a written calendar of tablet weeks and break weeks, prevents confusion. Many women find the treatment fits into daily life well once the first months pass.